TMC207: Phase II started

The TB Alliance began a double-blind, South African Phase II trial in 68 patients to evaluate TMC207, PA-824 and moxifloxacin for 14 days. Patients will receive TMC207 (700 mg on day 1,500 mg on day 2 and 400 mg on days 3-14) alone; TMC207 plus pyrazinamide; once-daily 200 mg PA-824 plus pyrazinamide; PA-824 plus pyrazinamide and 400 mg moxifloxacin; or Rifafour rifampicin/isoniazid/ethambutol/pyrimethamine as an active comparator. ...